JCOGP

As of January 2023, our "Journal of Controversies Obstetrics & Gynecology and Pediatrics" has been published under the Medihealth Academy to publish all articles, reviews and case reports on Pediatrics, especially in the field of Obstetrics and Gynecology. In order to facilitate the citation of the articles, to take our place in internationally respected indexes and to reach a wider readership, we will pay attention to the fact that our article language is only English in terms of acceptance.

EndNote Style
Index
Original Article
Investigation of serum prostate-specific antigen levels in pregnant women with gestational diabetes mellitus; a cross-sectional, case-control study
Aims: While many studies are showing that low serum prostate-specific antigen (PSA) levels are associated with the development of diabetes in male subjects, serum PSA levels in women with diabetes have not yet been investigated. Based on this information, we aimed to investigate serum PSA levels in pregnant women diagnosed with gestational diabetes mellitus (GDM).
Methods: This cross-sectional, case-control study was conducted with 88 pregnant women aged between 18 and 39 who applied to Umraniye Training and Research Hospital, Department of Obstetrics and Gynecology, Istanbul, Turkey, between May 2023 and September 2023. While the GDM group consisted of 44 pregnant women diagnosed with GDM between the 24th and 28th weeks of pregnancy, the control group consisted of 44 healthy pregnant women with normal 75-g oral glucose tolerance test (OGTT) results. Both groups were compared in terms of serum PSA levels.
Results: GDM and control groups were similar in terms of demographic features (p > 0.005). The gestational week and BMI at blood sampling for serum PSA level were similar in the two groups (p=0.801, p = 0.383, respectively). The median serum PSA level was found to be 1.22 ng/ml in the GDM group, while it was determined as 1.36 ng/ml in the control group (p=0.155)
Conclusion: The serum PSA level was lower in the GDM group than in the non-GDM group, yet this difference was not significant. Although the number of participants is too small to draw a definitive conclusion, serum PSA does not appear to be involved in the pathophysiology of GDM.


1. Lilja H, Oldbring J, Rannevik G, Laurell CB. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest. 1987;80(2):281-285. doi:10.1172/JCI113070
2. Carlsson SV, Vickers AJ. Screening for prostate cancer. Med Clin North Am. 2020;104(6):1051-1062. doi:10.1016/j.mcna.2020.08.007
3. Dash P. Reconnoitring the status of prostate specific antigen and its role in women. Indian J Clin Biochem. 2015;30(2):124-133. doi:10.1007/s12291-014-0451-3
4. Diamandis EP, Yu H. New biological functions of prostate-specific antigen? J Clin Endocrinol Metab. 1995;80(5):1515-1517. doi:10.1210/jcem.80.5.7538144
5. Ulutin HC, Pak Y. Prostate specific antigen in the female body: its role in breast cancer prognosis. Radiat Med. 2000;18(5):273-276.
6. Khatab Z, Prassas I, Stengelin M, Diamandis EP. Prostate-specific antigen and female breast cancer—revisited. J Appl Lab Med. 2023;8(3): 649-653. doi:10.1093/jalm/jfad002
7. Nagar R, Msalati AA. Changes in serum PSA during normal menstrual cycle. Indian J Clin Biochem. 2013;28(1):84-89. doi:10.1007/s12291-012-0263-2
8. Aksoy H, Akçay F, Umudum Z, Yildirim AK, Memisogullari R. Changes of PSA concentrations in serum and saliva of healthy women during the menstrual cycle. Ann Clin Lab Sci. 2002;32(1):31-36.
9. Maleki-Hajiagha A, Razavi M, Rezaeinejad M, et al. Serum prostate-specific antigen level in women with polycystic ovary syndrome: a systematic review and meta-analysis. Horm Metab Res. 2019;51(04):230-242. doi:10.1055/a-0863-5779
10. Xu H, Jiang HW, Ding GX, et al. Diabetes mellitus and prostate cancer risk of different grade or stage: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2013;99(3):241-249. doi:10.1016/j.diabres.2012. 12.003
11. Rastmanesh R, Hejazi J, Marotta F, Hara N. Type 2 diabetes: a protective factor for prostate cancer? An overview of proposed mechanisms. Clin Genitourin Cancer. 2014;12(3):143-148. doi:10.1016/j.clgc.2014.01.001
12. De Nunzio C, Tubaro A. Diabetes and prostate cancer—an open debate. Nat Rev Urol. 2013;10(1):12-14. doi:10.1038/nrurol.2012.239
13. Pierce BL. Why are diabetics at reduced risk for prostate cancer? A review of the epidemiologic evidence. Urol Oncol Semin Orig Investig. 2012;30(5):735-743. doi:10.1016/j.urolonc.2012.07.008
14. Bernal-Soriano MC, Lumbreras B, Hernández-Aguado I, Pastor-Valero M, López-Garrigos M, Parker LA. Untangling the association between prostate-specific antigen and diabetes: a systematic review and meta-analysis. Clin Chem Lab Med CCLM. 2021;59(1):11-26. doi:10.1515/cclm-2020-0145
15. Werny DM, Saraiya M, Gregg EW. Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002. Am J Epidemiol. 2006; 164(10):978-983. doi:10.1093/aje/kwj311
16. Al-Asadi J, Al-Naama L, Abdul-Kareem M, Mashkoor F. Serum level of prostate-specific antigen in diabetic patients in Basrah, Iraq. Niger Postgrad Med J. 2017;24(4):240. doi:10.4103/npmj.npmj_174_17
17. International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33(3):676-682. doi:10. 2337/dc09-1848
18. Chen M, Luo Y, Yang S, et al. Association of diabetes mellitus with prostate cancer grade and prostate-specific antigen in Chinese biopsy population. Diabetes Res Clin Pract. 2018;141:80-87. doi:10.1016/j.diabres.2018.04.022
19. Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA. Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol. 2009;169(8):937-945. doi:10.1093/aje/kwp003
20. Müller H, Raum E, Rothenbacher D, Stegmaier C, Brenner H. Association of diabetes and body-mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values? Cancer Epidemiol Biomarkers Prev. 2009;18(5):1350-1356. doi:10.1158/1055-9965.EPI-08-0794
21. Kobayashi M, Mizuno T, Yuki H, et al. Association between serum prostate-specific antigen level and diabetes, obesity, hypertension, and the laboratory parameters related to glucose tolerance, hepatic function, and lipid profile: implications for modification of prostate-specific antigen threshold. Int J Clin Oncol. 2020;25(3):472-478. doi:10.1007/s10147-019-01527-6
22. Naito M, Asai Y, Mori A, et al. Association of obesity and diabetes with serum prostate-specific antigen levels in Japanese males. Nagoya J Med Sci. 2012;74(3-4):285-292.
23. Ainahi A, Barakat A, Wakrim L, Mohammadi H, ElMdaghri N, Ezzikouri S. Prostate-specific antigen levels in moroccan diabetic males: a cross-sectional study. Curr Diabetes Rev. 2018;14(3):286-290. doi:10.2174/ 1573399813666170117113519
Volume 3, Issue 2, 2025
Page : 32-36
_Footer